================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 18, 2003
TRANSGENOMIC, INC.
(Exact name of registrant as specified in its charter)
Delaware 000-30975
(State of Formation) (Commission File Number)
911789357
(IRS Employer Identification Number)
12325 Emmet Street
Omaha, NE 68164
(Address of principal executive offices) (Zip Code)
(402) 452-5400
(Registrants' telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Item 5. Other Events and Regulation FD Disclosure.
On November 18, 2003, the Company issued a press release announcing it has
signed a contract with Austrian vaccine developer Intercell AG to develop a
manufacturing process for production of an immune stimulating oligonucleotide,
which will be used as a component of one or more of Intercell's novel vaccine
candidates. The Company is attaching the press release as Exhibit 99.1 to this
Current Report on Form 8-K.
Item 7. Financial Statements and Exhibits.
(c) Exhibits
99.1 Press Release, dated November 18, 2003, announcing Transgenomic has signed
a contract with Austrian vaccine developer Intercell AG to develop a
manufacturing process for production of an immune stimulating
oligonucleotide, which will be used as a component of one or more of
Intercell's novel vaccine candidates.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
TRANSGENOMIC, INC.
By /s/ Michael J. Draper
------------------------------------------
Michael J. Draper, Chief Financial Officer
November 18, 2003
2